Latest Insider Transactions at Transcode Therapeutics, Inc. (RNAZ)
This section provides a real-time view of insider transactions for Transcode Therapeutics, Inc. (RNAZ). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Transcode Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Transcode Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2023
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
98,000
+35.22%
|
$0
$0.51 P/Share
|
|
Sep 28
2023
|
Thomas A Fitzgerald Interim CEO, CFO |
BUY
Open market or private purchase
|
Direct |
49,350
+46.7%
|
$0
$0.51 P/Share
|
|
Jun 21
2023
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+12.73%
|
$24,000
$2.65 P/Share
|
|
Jun 20
2023
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,607
+8.6%
|
$13,214
$2.55 P/Share
|
|
Jun 09
2023
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
19,000
+2.04%
|
$38,000
$2.76 P/Share
|
|
Sep 14
2022
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+2.19%
|
$20,000
$1.15 P/Share
|
|
Jun 16
2022
|
Thomas A Fitzgerald Interim CEO, CFO |
BUY
Open market or private purchase
|
Direct |
12,000
+7.93%
|
$12,000
$1.27 P/Share
|
|
May 31
2022
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+0.23%
|
$2,000
$1.87 P/Share
|
|
May 27
2022
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
28,000
+3.11%
|
$28,000
$1.84 P/Share
|